Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 5, 2013, Pages 423-432

  Sun, Yaxin ^a   He, Xiaojing ^a   Qiu, Feng ^a   Zhu, Xu ^a   Zhao, Mingming ^a   Li Ling, Jesse ^b,c   Su, Xianying ^d   Zhao, Limei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NORTHEASTERN UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

^d Centre of Clinical Pharmacology   (China)

Author keywords

Arbidol; Chinese; Healthy subjects; Pharmacokinetics

Indexed keywords

ARBIDOL;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; INDOLES; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84878094725     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201843     Document Type: Article

References (39)

1. Arbidol. Drugs R D. 1999; 2: 171-172.
2. Boriskin YS, Leneva IA, Pécheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008; 15: 997-1005. CrossRef PubMed
3. Brooks MJ, Sasadeusz JJ, Tannock GA. Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? Curr Opin Pulm Med. 2004; 10: 197-203. CrossRef PubMed
4. Wang MZ, Cai BQ, Li LY, Lin JT, Su N, Yu HX, Gao H, Zhao JZ, Liu L. Efficacy and safety of arbidol in treatment of naturally acquired influenza. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004; 26: 289-293. PubMed
5. Drinevskǐ VP, Osidak LV, Natsina VK, Afanas'eva OI, Mil'kint KK, Danini GV, Ispolatova AV, Koreniako IE, Karelina NN, Marinich IG, Boldasov VK. Chemotherapeutics for treatment of influenza and other viral respiratory tract infections in children. Antibiot Khimioter. 1998; 43: 29-34. PubMed
6. Beliaev AL, Burtseva EI, Slepushkin AN, Beliaeva NA, Nosik NN, Lavrukhina LA, Maksimova LN, Feklisova LV, Shibekova VM, Danina NF, Tselipanova EE, Bylinkina SA, Voǐtsekhovskaia EM, Sominina AA. Arbidole - a new drug for prevention of influenza and acute viral respiratory infections in children. Vestn Ross Akad Med Nauk. 1996; 8: 34-37. PubMed
7. Gagarinova VM, Ignat'eva GS, Sinitskaia LV, Ivanova AM, Rodina MA, Tur'eva AV. [The new chemical preparation arbidol: its prophylactic efficacy during influenza epidemics]. Zh Mikrobiol Epidemiol Immunobiol. 1993; 5: 40-43. PubMed
8. Kolobukhina LV, Malinovskaia VV, Gatich RZ, Merkulova LN, Burtseva EI, Isaeva EI, Parshina OV, Guseva TS, Orlova TG, Voronina FV. Evaluation of the efficacy of wiferon and arbidol in adult influenza. Vopr Virusol. 2008; 53: 31-33. PubMed
9. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009; 81: 132-140.
10. Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, Cosset FL, Böckmann A, Meier BH, Penin F, Pécheur EI. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS ONE. 2011; 6: e15874. CrossRef PubMed
11. Villalaín J. Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes. J Phys Chem B. 2010; 114: 8544-8554. CrossRef PubMed
12. Zhong Q, Yang Z, Liu Y, Deng H, Xiao H, Shi L, He J. Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo. Arch Virol. 2009; 154: 601-607. CrossRef PubMed
13. Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, Hou W, Cheng L, Xiao H, Yang Z. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol. 2007; 152: 1447-1455. CrossRef PubMed
14. Leneva IA, Fediakina IT, Eropkin MIu, Gudova NV, Romanovskaia AA, Danilenko DM, Vinogradova SM, Lepeshkin AIu, Shestopalov AM. [Study of the antiviral activity of Russian anti-influenza agents in cell culture and animal models]. Vopr Virusol. 2010; 55: 19-27. PubMed
15. Khamitov RA, Loginova SIa, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. Vopr Virusol. 2008; 53: 9-13. PubMed
16. Fediakina IT, Shchelkanov MIu, Deriabin PG, Leneva IA, Gudova NV, Kondrat'eva TV, L'vov DK. Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture. Antibiot Khimioter. 2011; 56: 3-9. PubMed
17. Fediakina IT, Leneva IA, Iamnikova SS, Livov DK, Glushkov RG, Shuster AM. Sensitivity of influenza A/H5 viruses isolated from wild birds on the territory of Russia to arbidol in the cultured MDCK cells. Vopr Virusol. 2005; 50: 32-35. PubMed
18. Deng HY, Luo F, Shi LQ, Zhong Q, Liu YJ, Yang ZQ. Efficacy of arbidol on lethal hantaan virus infections in suckling mice and in vitro. Acta Pharmacol Sin. 2009; 30: 1015-1024.
19. Delogu I, Pastorino B, Baronti C, Nougairede A, Bonnet E, de Lamballerie X. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res. 2011; 90: 99-107.
20. Brooks MJ, Burtseva EI, Ellery PJ, Marsh GA, Lew AM, Slepushkin AN, Crowe SM, Tannock GA. Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol. 2012; 84: 170-181. CrossRef PubMed
21. Glushkov RG, Gus'kova TA, Krylova LIu, Nikolaeva IS. Mechanisms of arbidole'simmunomodulating action. Vestn Ross Akad Med Nauk. 1999; 3: 36-40. PubMed
22. Glushkov RG, Gus'kova TA. Arbidol: A new domestic immunomodulant (A review). Pharm Chem J. 1999; 33: 115-122. CrossRef
23. Glushkov RG, Fadeeva NI, Leneva IA, Gerasina SF, Budanova LI, Sokolova ND, Stebaeva LF, Kuzovkin VA, Degtyarev EV, Sokolova TM, Fedyakina IT. Molecular biological characteristics of the action of arbidol - a new antiviral drug. Pharm Chem J. 1992; 26: 106-115.
24. Pécheur EI, Lavillette D, Alcaras F, Molle J, Boriskin YS, Roberts M, Cosset FL, Polyak SJ. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry. 2007; 46: 6050-6059. CrossRef PubMed
25. Anisimova OS, Frolova LV, Chistyakov VV, Ermachenkov IA, Golovanova IV, Zotova SA, Pleshkova AP, Yadrovskaya VA, Sheinker YN. Study of metabolism of the antiviral drug arbidol by mass spectrometry, thin-layer and highperformance liquid chromatography. Pharm Chem J. 1995; 29: 78-82. CrossRef
26. Wang Y, Chen X, Li Q, Zhong D. Metabolite identification of arbidol in human urine by the study of CID fragmentation pathways using HPLC coupled with ion trap mass spectrometry. J Mass Spectrom. 2008; 43: 1099-1109. CrossRef PubMed
27. Guskova TA, Leneva IA, Fedyakina IT, Chistyakov VV, Glushkov RG. Arbidol kinetics and effect upon influenza type a virus reproduction in MDCK cell culture. Pharm Chem J. 1999; 33: 62-64. CrossRef
28. Metz R, Muth P, Ferger M, Kukes VG, Vergin H. Sensitive high-performance liquid chromatographic determination of arbidol, a new antiviral compound in human plasma. J Chromatogr A. 1998; 810: 63-69. CrossRef PubMed
29. Liu MY, Wang S, Yao WF, Wu HZ, Meng SN, Wei MJ. Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009; 31: 784-792.
30. Liu X, Huang YW, Li J, Li XB, Bi KS, Chen XH. Determination of arbidol in human plasma by LCESI-MS. J Pharm Biomed Anal. 2007; 43: 371-375.
31. Feng YF, Lv JL, Song LJ, Li KX, Sun CH. Pharmacokinetics and relative bioavailability of arbidol hydrochloride tablets and capsules in Chinese healthy volunteers. Chinese Pharmaceutical Journal. 2008; 43: 1257-1260.
32. Li XL, Zhang ZC, Feng WY. Determination of arbidol in human plasma by HPLC and its pharmacokinetics. Journal of Shenyang Pharmaceutical University. 2009; 26: 997-1000.
33. Ren YH, Sun JX, Jiang H, Shen JP, Zhang YD, Zhang ZX. Pharmacokinefics and bioequivalence of arbidol hydrochloride granules in human plasma. Chinese Pharmaceutical Journal. 2006; 41: 1814-1817.
34. Sun YQ, Zhang SH, Qiu ZH, He LE, Ma J. Bioequivalence of arbidol tablets and capsules. Chinese Pharmaceutical Journal. 2009; 44: 49-52.
35. Song LJ, Feng YF, Li KX, Sun CH, Hu X, Wang WH. Relative bioavailability of arbidol hydrochloride granule, suspension and capsule in healthy volunteers. The Chinese Journal of Clinical Pharmacology. 2007; 23: 292-295.
36. Yan Y, Feng YF, Li KX, Chen WX, Shen ZY. HPLC determination and pharmacokinetic study of arbidol in human plasma. Chinese Journal of Pharmaceutical Analysis. 2007; 27: 817-820.
37. Yang H, Zhang S, Feng X. Determination of arbidol in human plasma by HPLC and Its pharmacokinetics. Chinese Journal of Pharmaceuticals. 2008; 39: 359-361.
38. Liu X, Si DD, Bi KS, Chen XH. Bioequivalence of arbidol hydrochloride dispersibe tablets in healthy volunteers. Chinese Journal of Pharmaceutical Analysis. 2007; 27: 828-830.
39. Liu HB, Qu WX, Li SQ, Sun JM, Miao LN, Jia Y, Zhang J, Dang BW, Li Y, Liang Y, Yang JH, Zhang W, Li YC, Pan DZ. Multicenter randomized double blind parallel clinical trial of arbidol hydrochloride tablet in the treatment of naturally acquired influenza. The Chinese Journal of Clinical Pharmacology. 2006; 22: 403-405.